Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

MARCH 2, 2020

This landmark approval is unique in that ketamine is well known to have hallucinogenic properties, as well as a long history as a party drug. Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). Fortunately, this issue shouldn’t be a show-stopper. Potential IPOs within the next year.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Cannabis Law Report

MARCH 21, 2019

Although the DEA refuses to remove marijuana from the schedule 1 list, the Farm Bill is considered to be the most important victory in the history of U.S. Schedule 1 drugs are substances, chemicals, or drugs considered by the federal government to have no medical use and a high potential for abuse such as heroin, LSD, and ecstasy.

State Laws 55

State Laws Law CBD Legalization 55

SpeedWeed

DECEMBER 28, 2018

On October 17, Canada made history by becoming the second nation (after Uruguay) to federally legalize adult-use cannabis. There’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval. Buzz: Canada Legalizes Adult-Use Cannabis.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40

Canna Law Blog

NOVEMBER 27, 2021

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.”

Therapy 98

Therapy Clinical Trials DEA Microdosing 98

Veriheal

DECEMBER 21, 2022

This makes history by enacting the first piece of standalone federal cannabis reform legislation in U.S. The Drug Enforcement Administration (DEA) is now mandated to approve applications to be manufacturers of marijuana-derived, FDA-approved drugs under the bill. The law gives the U.S. The law gives the U.S.

Clinical Trials 98

Clinical Trials Marijuana Decriminalization History 98

Veriheal

AUGUST 31, 2020

However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. Supply chains are disrupted as a result, and consumers grow fearful of buying hemp.

Research and Development 119

Research and Development Education Agriculture Patients 119

Canna Law Blog

JANUARY 3, 2023

A little CBD history. Until recently, CBD resided in a legal penumbra where hemp was still scheduled on the federal Controlled Substances Act and could not be cultivated without a permit from the Drug Enforcement Administration (“DEA”).

CBD 98

CBD Food Clinical Trials Pets 98

SpeedWeed

MARCH 18, 2021

They also wrote: The study sample included participants with a history of cannabis use. Given the topical nature of the current trial and its relevance for public policy on medical cannabis, participants might have been biased to report positive effects regardless of condition. It tested at only 9% THC. Establishing cannabis as safe.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. Trial of Psilocybin Versus Escitalopram for Depression , 384 NEW ENG. Mitchell et al.,

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Veriheal

NOVEMBER 7, 2024

The Drug Enforcement Administration (DEA) announced in August that a hearing regarding the reclassification decision will take place on December 2, 2024, before an administrative law judge. Then, the DEA will review the report and draft a final ruling, factoring in all relevant information submitted during the public comment period.

DEA 97

DEA Policy Chronic Pain Marijuana 97